| Literature DB >> 29192133 |
Graham S Erwin1, Matthew P Grieshop1, Asfa Ali1, Jun Qi2, Matthew Lawlor2, Deepak Kumar3,4, Istaq Ahmad3,4, Anna McNally5, Natalia Teider5, Katie Worringer5, Rajeev Sivasankaran5, Deeba N Syed6, Asuka Eguchi1, Md Ashraf1, Justin Jeffery7, Mousheng Xu2, Paul M C Park2, Hasan Mukhtar6, Achal K Srivastava3, Mohammed Faruq4, James E Bradner2,5, Aseem Z Ansari8,9.
Abstract
The release of paused RNA polymerase II into productive elongation is highly regulated, especially at genes that affect human development and disease. To exert control over this rate-limiting step, we designed sequence-specific synthetic transcription elongation factors (Syn-TEFs). These molecules are composed of programmable DNA-binding ligands flexibly tethered to a small molecule that engages the transcription elongation machinery. By limiting activity to targeted loci, Syn-TEFs convert constituent modules from broad-spectrum inhibitors of transcription into gene-specific stimulators. Here we present Syn-TEF1, a molecule that actively enables transcription across repressive GAA repeats that silence frataxin expression in Friedreich's ataxia, a terminal neurodegenerative disease with no effective therapy. The modular design of Syn-TEF1 defines a general framework for developing a class of molecules that license transcription elongation at targeted genomic loci.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29192133 PMCID: PMC6037176 DOI: 10.1126/science.aan6414
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728